1H3.SI Clearbridge Health (SES) up 100.00% to S$0.002 on 12 Mar 2026: After-hours volume watch

The 1H3.SI stock surged 100.00% to S$0.002 in after-hours trading on 12 Mar 2026, driven by a sharp intraday move from S$0.001. Trading volume remained light at 5,500 shares but stands out versus the immediate prior session given the stock’s average volume of 4,351,464.00. This note breaks down the price action on the Singapore Exchange (SES), links the move to company context and sector trends, and outlines what investors should watch next for Clearbridge Health Limited (1H3.SI).

1H3.SI stock: Price action and volume

Clearbridge Health (1H3.SI) closed after hours at S$0.002, up 100.00% from the previous close of S$0.001, with reported volume of 5,500. The day range was S$0.002–S$0.002, and the trade lifted market capitalization to approximately S$4,295,821.00, keeping the stock far below its year high S$0.005 and above its year low S$0.001.

1H3.SI stock: What could have driven the move

There is no formal market announcement tied to the spike; the move looks like short-term speculative trading or microcap order flow rather than earnings news. Investors should check company releases and SGX listings for updates and regulatory notices; Clearbridge’s site posts corporate updates source and SGX listings can confirm any formal filings source.

1H3.SI stock: Financials and valuation

On trailing metrics Clearbridge shows a P/B of 0.13 and P/S of 0.58, while EPS is not applicable and the TTM net income per share is -0.00130. The balance sheet shows a current ratio of 1.73 and debt to equity near 0.12, indicating modest leverage but negative profitability and free cash flow per share of -0.00076.

Technical view and Meyka grade for 1H3.SI stock

Technically the stock sits near oversold indicators—RSI 35.04 and CCI -165.93—with erratic volume relative to the 50-day average S$0.00196 and 200-day average S$0.00252. Meyka AI rates 1H3.SI with a score out of 100: Meyka AI rates 1H3.SI with a score out of 100 at 61.72 (Grade B, HOLD). This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus.

1H3.SI stock: Risks and catalysts to monitor

Key risks are continued low liquidity—average volume 4,351,464.00 versus today’s 5,500—negative net income per share, and limited analyst coverage (no consensus price target). Catalysts would include corporate disclosures, clinical or contract wins in the Healthcare segment, or meaningful insider or strategic investor activity.

1H3.SI stock: Price targets and Meyka AI forecast

Meyka AI’s forecast model projects a 12-month baseline of S$0.00512, a 3-year S$0.01168, and a 5‑year S$0.01822. Short-term pragmatic price targets we track are S$0.003 (near-term), S$0.005 (12 months), and S$0.0117 (3 years), reflecting model outputs and sector comparables. Forecasts are model-based projections and not guarantees.

Final Thoughts

After-hours action on 12 Mar 2026 left 1H3.SI stock at S$0.002, a 100.00% move from the prior close but on modest 5,500 shares traded. The spike appears driven by microcap flow rather than new fundamental information; Clearbridge Health’s financials show a negative EPS and modest leverage, with P/B 0.13 and TTM net income per share -0.00130, underlining operating weakness despite low valuation multiples. Meyka AI’s forecast model projects S$0.00512 in 12 months, implying an upside of 156.22% from the current price of S$0.002; forecasts are model-based projections and not guarantees. For traders, this remains a high-risk, low-liquidity play on SES; for longer-term investors, watch for confirmed corporate news, meaningful volume increases and improvements in profitability before increasing exposure. Remember Meyka AI is an AI-powered market analysis platform and this note reflects data-driven context, not investment advice.

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.